Abstract 2877
Background
The purpose of this study was to explore the impact of completeness of weekly irinotecan combined with capecitabine-based preoperative chemoradiotherapy in patients with locally advanced rectal cancer (LARC).
Methods
LARC patients receiving neoadjuvant CRT between May 2011 and February 2018 were enrolled. The paradigm included preoperative pelvic RT (50 Gy/25Fx) concurrently with capecitabine (625 mg/m2, bid, d1-5) and irinotecan (80 mg/m2 for UGT1A1*1*1 genotype or 65 mg/m2 for UGT1A1*1*28 genotype, qw), followed by a course of XELIRI and surgery. The actual cycles of concurrent irinotecan delivered was reviewed from the electronic records. Patients were divided into the low-completeness group (1∼3 cycles) and the high-completeness group (4∼5 cycles). Univariate and multivariate analyses were performed to identify risk factors of the completeness. A nomogram was built to divide patients into 3 groups with different risk.
Results
A total of 371 patients were enrolled, with 102 patients from a phase III clinical trial (CinClare, NCT02605265). The proportion of patients with low completeness was 32.4% versus 67.6% with high completeness in the CinClare group, and 41.3% versus 58.7% in the remaining group (p = 0.12). In the CinClare group, the complete response (CR) rate was 24.2% in the low-completeness patients versus 42.6% in the high-completeness patients (p = 0.07). The difference was more significant in the general population (28.6% vs 71.6%, p = 0.02). Univariate analysis showed age over 60, female, anemia at baseline, and a low pretreatment pre-Alb level were associated with a low completeness. By using multivariate analysis and building a nomogram, we could divide patients into 3 groups: (1) high-risk group (risk score>200); (2) intermediate-risk group (score 100∼200); (3) low-risk group (score≤100). The rates of high completeness in the 3 groups were 27.8%, 47.6% and 69.5%, respectively.
Conclusions
Our analysis suggested a higher completeness of weekly irinotecan was associated with a higher CR rate. Comprehensive evaluation of the patient performance is necessary before starting the intensified treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3034 - Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL STUDY
Presenter: Maria Agnese Fabbri
Session: Poster Display session 2
Resources:
Abstract
4772 - Real world comparison of the impact of adjuvant capecitabine in women with high-risk triple-negative breast cancer after neoadjuvant chemotherapy
Presenter: Maysa Vilbert
Session: Poster Display session 2
Resources:
Abstract
5627 - Influence of age on the indication of adjuvant chemotherapy in early breast cancer using Oncotype DX. An analysis of 240 patients treated in the Institut Catala d’Oncologia (ICO) hospitals
Presenter: Sabela Recalde
Session: Poster Display session 2
Resources:
Abstract
3917 - Impact of delayed neoadjuvant systemic chemotherapy on survival among breast cancer patients
Presenter: Mariana Chavez Mac Gregor
Session: Poster Display session 2
Resources:
Abstract
2246 - Clinical Confirmation of Higher Exposure to Niraparib in Tumor vs Plasma in Patients With Breast Cancer
Presenter: Laura Spring
Session: Poster Display session 2
Resources:
Abstract
581 - The rationale for the effectiveness of systemic treatment of breast cancer depending on the body weight index
Presenter: Mohammad Hojouj
Session: Poster Display session 2
Resources:
Abstract
5327 - Response to neoadjuvant chemotherapy in HER2 non-overexpressing breast cancer subtypes
Presenter: Silvia Mihaela Ilie
Session: Poster Display session 2
Resources:
Abstract
3613 - Pre-specified interim analysis of the SAFE trial (NCT2236806): a 4-arm randomized, double-blind, controlled study evaluating the efficacy and safety of cardiotoxicity prevention in non-metastatic breast cancer patients treated with anthracyclines with or without trastuzumab.
Presenter: Lorenzo Livi
Session: Poster Display session 2
Resources:
Abstract
3736 - Safety of hypofractionated whole breast irradiation after conservative surgery for patients aged less than 60 years: a multi-center comparative study.
Presenter: Icro Meattini
Session: Poster Display session 2
Resources:
Abstract
5085 - Usefulness of NT-ProBNP as a biomarker of cardiotoxicity in breast cancer patients treated with trastuzumab
Presenter: Isabel Blancas López-Barajas
Session: Poster Display session 2
Resources:
Abstract